Helicobacter pylori infection is one of the most common causes of gastritis, peptic ulcers, and even stomach cancer. Antibiotics are traditionally used to treat it, but growing antibiotic resistance has created an urgent need to find alternative treatments. One promising approach is the use of bacteriophages—natural viruses that specialize in killing bacteria.

How phages affect Helicobacter pylori

Bacteriophages operate on the principle of specific infection: they recognize specific bacteria, penetrate them, and destroy them from the inside. This feature of phages makes them very promising for combating pathogens such as Helicobacter pylori.

Studies have shown that certain specially selected bacteriophage strains can effectively infect and destroy Helicobacter pylori cells. Due to their narrow specialization, bacteriophages do not harm the body's beneficial microflora, a significant advantage over antibiotics, which often cause dysbiosis.

However, for phage therapy to be effective against Helicobacter pylori infection, the challenging conditions of the stomach environment must be taken into account. High stomach acidity can reduce phage activity, so scientists are developing special capsules that protect bacterial viruses until they reach the target site.

Benefits of phage therapy in the treatment of Helicobacter pylori

One of the main advantages of using bacteriophages is their high specificity. They specifically destroy Helicobacter pylori without disturbing the balance of other bacteria in the stomach and intestines.

Furthermore, phages have the ability to evolve alongside bacteria. This means that even if Helicobacter pylori undergoes certain changes, the "good viruses" can adapt and continue their activity, unlike antibiotics, which are static by nature.

Another important advantage is the minimal side effects. With phage therapy, the risk of allergic reactions or toxic liver damage is significantly lower than with traditional antibiotic treatment.

Scientists also note the potential of combining bacteriophages with low-dose antibiotics. This approach could significantly improve the effectiveness of therapy and prevent the development of antibiotic resistance.

Is phage therapy available for the treatment of Helicobacter pylori infections?

Despite numerous promising prospects, phage therapy for Helicobacter pylori infections is still in the active research phase. Clinical trials are already underway in some countries, showing encouraging results.

However, there are currently no officially approved drugs for the treatment of Helicobacter pylori using bacteriophages. This is due to the need for rigorous testing for safety and efficacy.

In the near future, we can expect the emergence of specialized phage products targeting Helicobacter pylori. This will significantly expand physicians' therapeutic options and provide patients with new, more effective treatments.

In the meantime, patients are advised to consult with a gastroenterologist and participate in clinical trials only under medical supervision.